Results 41 to 50 of about 8,298 (167)

Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda

Malaria Journal, 2006
Background A six-dose antimalarial regimen of artemether-lumefantrine (A/L) may soon become one of the most widely used drug combination in Africa, despite possible constraints with adherence and poor absorption due to inadequate nutrition, and a lack of
Ruzagira Eugene, Grandesso Francesco, Biraro Samuel, Bajunirwe Francis, Fogg Carole, Piola Patrice, Checchi Francesco, Babigumira Joseph, Kigozi Isaac, Kiguli James, Kyomuhendo Juliet, Ferradini Laurent, Taylor Walter RJ, Guthmann Jean-Paul   +13 more
doaj   +1 more source

Short‐Course Low‐Dose Primaquine for Radical Cure in G6PD‐Normal Patients in the Pre‐Elimination Context of Nepal

Tropical Medicine &International Health, Volume 31, Issue 8, Page 1028-1034, August 2026.
ABSTRACT Background Plasmodium vivax remains a challenge for malaria elimination in Nepal due to its ability to relapse. Radical cure with primaquine is effective but limited by poor adherence to the standard 14‐day low‐dose regimen. In 2022, the WHO recommended administering the same total dose (3.5 mg/kg) over 7 days to improve adherence.
Prakash Ghimire, Gokarna Dahal, Nabaraj Adhikari, Komal Raj Rijal, Sanjib Adhikari, Megha Raj Banjara, Hellen Mnjala, Grant Lee, Sophie Weston, Angela Rumaseb, Anjana Rai, Benedikt Ley, Mohammad Sharif Hossain, Julie A. Simpson, Megha Rajasekhar, Bipin Adhikari, Ric N. Price, Bibek K. Lal, Kamala Thriemer   +18 more
wiley   +1 more source

PHARMACOKINETICS OF LUMEFANTRINE IN HEALTHY PAKISTANI VOLUNTEERS

Pakistan Armed Forces Medical Journal, 2011
Objective: To study the pharmacokinetics of lumefantrine in healthy Pakistani volunteers so as to see the adequacy of the regimen in vogue for the treatment of malaria and prevention of recrudescence.
Nusrat Jafery, Muzammil Hassan Najmi
doaj   +2 more sources

Can hair concentrations of artemether-lumefantrine be used as a tool to retrospectively determine drug exposure during malaria treatment?

New Microbes and New Infections
Background: Artemether-lumefantrine (AL) is the first-line treatment for uncomplicated Plasmodium falciparum malaria, with cure rates exceeding 95 %.
Jenny L. Schnyder, Marloes Vos-van der Meer, Reinier M. van Hest, Ron Mathot, Patricia Schlagenhauf, Hanna K. de Jong, Martin P. Grobusch   +6 more
doaj   +1 more source

Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.

PLoS ONE, 2017
BackgroundThe antiretroviral drug nevirapine and the antimalarial artemisinin-based combination therapy artemether-lumefantrine are commonly co-administered to treat malaria in the context of HIV.
Liusheng Huang, Vincent Carey, Jane C Lindsey, Florence Marzan, David Gingrich, Bobbie Graham, Linda Barlow-Mosha, Phionah K Ssemambo, Portia Kamthunzi, Sharon Nachman, Sunil Parikh, Francesca T Aweeka, IMPAACT P1079 protocol team   +12 more
doaj   +1 more source

Incompatibility of antimalarial drugs: challenges in formulating combination products for malaria

Drug Delivery
Lipophilic drugs require more advance formulation, especially if the intention is to make solutions or semisolid formulations. This also accounts for most antimalarial drugs. Although some of these antimalarial drugs are soluble in lipid vehicles, few of
Ellen K. G. Mhango, Benjamin R. Sveinbjornsson, Bergthora S. Snorradottir, Sveinbjorn Gizurarson   +3 more
doaj   +1 more source

Pyronaridine–artesunate and artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial

Malaria Journal, 2018
Background Pyronaridine–artesunate is a novel artemisinin-based combination therapy. The efficacy and safety of pyronaridine–artesunate were compared with artemether–lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in ...
Johanna M. Roth, Patrick Sawa, Nicodemus Makio, George Omweri, Victor Osoti, Selpha Okach, Felix Choy, Henk D. F. H. Schallig, Pètra Mens   +8 more
doaj   +1 more source

Gossypiboma‐Induced Acute Abdomen Highlighting the Importance of Surgical Safety Protocols: A Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Gossypiboma, the medical term for a retained surgical sponge, is a rare but serious postoperative complication, accounting for nearly 50% of malpractice claims related to retained foreign bodies. Despite its importance, it is often underreported due to medicolegal concerns.
Priyanka Panwar, Jack Okumu, Daisy Denga, James Kariuki, O. W. Sibuor   +4 more
wiley   +1 more source

Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.

PLoS Medicine, 2018
BackgroundThe fixed dose combination of artemether-lumefantrine (AL) is the most widely used treatment for uncomplicated Plasmodium falciparum malaria.
Frank Kloprogge, Lesley Workman, Steffen Borrmann, Mamadou Tékété, Gilbert Lefèvre, Kamal Hamed, Patrice Piola, Johan Ursing, Poul Erik Kofoed, Andreas Mårtensson, Billy Ngasala, Anders Björkman, Michael Ashton, Sofia Friberg Hietala, Francesca Aweeka, Sunil Parikh, Leah Mwai, Timothy M E Davis, Harin Karunajeewa, Sam Salman, Francesco Checchi, Carole Fogg, Paul N Newton, Mayfong Mayxay, Philippe Deloron, Jean François Faucher, François Nosten, Elizabeth A Ashley, Rose McGready, Michele van Vugt, Stephane Proux, Ric N Price, Juntra Karbwang, Farkad Ezzet, Rajesh Bakshi, Kasia Stepniewska, Nicholas J White, Philippe J Guerin, Karen I Barnes, Joel Tarning   +39 more
doaj   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source